The corporate venturing unit of GlaxoSmithKline joins Imperial Innovations, Invesco Perpetual and Lundbeckfond Ventures backing the UK-based cancer treatment company.
UK-based pharmaceuticals company GlaxoSmithKline’s corporate venturing unit has helped PsiOxus Therapeutics, a UK-based cancer treatment company, raise £22m ($34m) in a series B round today.
The deal was the second from SR One’s UK fund, according to Matthew Foy, a partner at SR One. Foy added: “Mission Therapeutics was the first deal and additionally we use the fund to continue to support investment in our pre-existing UK portfolio companies.”
SR One was joined in the round by university-backed and UK-listed…
